Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

View original at finance.yahoo.com
Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years? What a ride it has been for Apple(NASDAQ: AAPL) and its shareholders over the years…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Apple generates a 68% return on invested capital

    60% confidence
  • Apple is reportedly developing AI glasses that would represent a brand-new product category

    60% confidence
  • Electronic devices are becoming increasingly central to modern life, so the iOS ecosystem should have long-term staying power

    60% confidence
  • The iPhone is the most popular smartphone in the United States, with a 50% to 65% market share

    60% confidence
  • Apple generated more than $123 billion in free cash flow over the past four quarters

    60% confidence
  • Apple evolved from an underdog in the computer market to arguably the world's most prominent consumer-facing business today

    60% confidence
  • iPhone accounts for an estimated 32% of the global smartphone market

    60% confidence
  • Apple is still a no-brainer to buy and hold

    60% confidence
  • There are now 2.5 billion active iOS devices worldwide

    60% confidence
  • Given Apple's $3.75 trillion market cap, investors shouldn't anticipate future performance to rival the past

    60% confidence
  • Apple stock has returned over 97,000% since 1990, including dividends

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com